Telomir Pharmaceuticals, Inc. (TELO) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.17

From 52W high−36.27%

Volume475613.00

Market cap$84.59M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.17

From 52W high

−36.27%

Volume

475613.00

Market cap

$84.59M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−13.5x

P/E (TTM)

—

RSI (14)

49.8

MomentumView details →

1D Return

+9.82%

YTD Return

−13.16%

SummaryUpdated Jun 1, 2026

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage biotechnology company founded in 2021 and headquartered in Baltimore, Maryland. The company was formerly known as Metallo Therapies Inc. before changing its name in October 2022. Telomir went public in April 2019 and focuses on developing therapeutic treatments targeting human stem cells and age-related inflammatory conditions. As a pre-clinical company, Telomir has not yet generated revenue and is currently in the research and development phase of bringing its lead drug candidate to market.

Ask drillr about Telomir Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−13.5x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

16.8x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−116.74%

ROA (TTM)

−109.51%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

−55.14%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+41.07%

EBITDA YoY

+63.62%

MomentumView details →

1D Return

+9.82%

YTD Return

−13.16%

1Y Return

−24.51%

RSI (14)

49.8

vs 50D SMA

+0.08%

vs 200D SMA

−8.71%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

16.14x

Quick Ratio

16.14x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.79

EPS Surprise

−1028.57%

Beats (12Q)

2/12

Next Q EPS Est

−$0.03

Avg Surprise (4Q)

−264.73%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−5.88M

Op. CF (TTM)

−4.91M

Next earningsDec 2, 2026 →

Latest newsMore news →

Telomir Pharmaceuticals announced research findings from The Ohio State University College of Veterinary Medicine showing that Telomir-Zn inhibits cell growth in human and canine osteosarcoma models.6d ago

Similar companies

Fortress Biotech, Inc.FBIO Adicet Bio, Inc.ACET Aldeyra Therapeutics, Inc.ALDX Connect Biopharma Holdings LimitedCNTB iBio, Inc.IBIO Lixte Biotechnology Holdings, Inc.LIXT Find similar companies →

Latest newsMore news →